201 related articles for article (PubMed ID: 16237064)
1. Ex vivo rapamycin generates donor Th2 cells that potently inhibit graft-versus-host disease and graft-versus-tumor effects via an IL-4-dependent mechanism.
Foley JE; Jung U; Miera A; Borenstein T; Mariotti J; Eckhaus M; Bierer BE; Fowler DH
J Immunol; 2005 Nov; 175(9):5732-43. PubMed ID: 16237064
[TBL] [Abstract][Full Text] [Related]
2. Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy.
Jung U; Foley JE; Erdmann AA; Toda Y; Borenstein T; Mariotti J; Fowler DH
Biol Blood Marrow Transplant; 2006 Sep; 12(9):905-18. PubMed ID: 16920556
[TBL] [Abstract][Full Text] [Related]
3. Th2 cell therapy of established acute graft-versus-host disease requires IL-4 and IL-10 and is abrogated by IL-2 or host-type antigen-presenting cells.
Foley JE; Mariotti J; Ryan K; Eckhaus M; Fowler DH
Biol Blood Marrow Transplant; 2008 Sep; 14(9):959-972. PubMed ID: 18721759
[TBL] [Abstract][Full Text] [Related]
4. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
[TBL] [Abstract][Full Text] [Related]
5. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Vallera DA
J Immunol; 1998 Jun; 160(11):5355-65. PubMed ID: 9605135
[TBL] [Abstract][Full Text] [Related]
6. Ex vivo rapamycin generates apoptosis-resistant donor Th2 cells that persist in vivo and prevent hemopoietic stem cell graft rejection.
Mariotti J; Foley J; Jung U; Borenstein T; Kantardzic N; Han S; Hanson JT; Wong E; Buxhoeveden N; Trepel JB; Fojo AT; Telford W; Fowler DH
J Immunol; 2008 Jan; 180(1):89-105. PubMed ID: 18097008
[TBL] [Abstract][Full Text] [Related]
7. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
[TBL] [Abstract][Full Text] [Related]
8. CD3/CD28-costimulated T1 and T2 subsets: differential in vivo allosensitization generates distinct GVT and GVHD effects.
Jung U; Foley JE; Erdmann AA; Eckhaus MA; Fowler DH
Blood; 2003 Nov; 102(9):3439-46. PubMed ID: 12855580
[TBL] [Abstract][Full Text] [Related]
9. Murine recipients of fully mismatched donor marrow are protected from lethal graft-versus-host disease by the in vivo administration of rapamycin but develop an autoimmune-like syndrome.
Blazar BR; Taylor PA; Snover DC; Sehgal SN; Vallera DA
J Immunol; 1993 Nov; 151(10):5726-41. PubMed ID: 8228258
[TBL] [Abstract][Full Text] [Related]
10. Rapamycin-resistant effector T-cell therapy.
Fowler DH
Immunol Rev; 2014 Jan; 257(1):210-25. PubMed ID: 24329799
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice.
Murphy WJ; Welniak LA; Taub DD; Wiltrout RH; Taylor PA; Vallera DA; Kopf M; Young H; Longo DL; Blazar BR
J Clin Invest; 1998 Nov; 102(9):1742-8. PubMed ID: 9802888
[TBL] [Abstract][Full Text] [Related]
12. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease.
Anderson LD; Mori S; Mann S; Savary CA; Mullen CA
Cancer Res; 2000 Oct; 60(20):5797-802. PubMed ID: 11059776
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of graft-versus-host disease by interleukin-2 treatment is associated with altered cytokine production by expanded graft-versus-host-reactive CD4+ helper cells.
Wang MG; Szebeni J; Pearson DA; Szot GL; Sykes M
Transplantation; 1995 Sep; 60(5):481-90. PubMed ID: 7676498
[TBL] [Abstract][Full Text] [Related]
14. Reconstructing immunity after allogeneic transplantation.
Giver CR; Li JM; Hossain MS; Lonial S; Waller EK
Immunol Res; 2004; 29(1-3):269-82. PubMed ID: 15181288
[TBL] [Abstract][Full Text] [Related]
15. IFN-γ receptor-deficient donor T cells mediate protection from graft-versus-host disease and preserve graft-versus-tumor responses after allogeneic bone marrow transplantation.
Sun K; Hsiao HH; Li M; Ames E; Bouchlaka M; Welniak LA; Hagino T; Jagdeo J; Pai CC; Chen M; Blazar BR; Abedi M; Murphy WJ
J Immunol; 2012 Aug; 189(4):2033-42. PubMed ID: 22778394
[TBL] [Abstract][Full Text] [Related]
16. Co-stimulated/Tc2 cells abrogate murine marrow graft rejection.
Erdmann AA; Jung U; Foley JE; Toda Y; Fowler DH
Biol Blood Marrow Transplant; 2004 Sep; 10(9):604-13. PubMed ID: 15319772
[TBL] [Abstract][Full Text] [Related]
17. Rapamycin, a potent inhibitor of T-cell function, prevents graft rejection in murine recipients of allogeneic T-cell-depleted donor marrow.
Blazar BR; Taylor PA; Sehgal SN; Vallera DA
Blood; 1994 Jan; 83(2):600-9. PubMed ID: 8286755
[TBL] [Abstract][Full Text] [Related]
18. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells.
Shin HJ; Baker J; Leveson-Gower DB; Smith AT; Sega EI; Negrin RS
Blood; 2011 Aug; 118(8):2342-50. PubMed ID: 21734238
[TBL] [Abstract][Full Text] [Related]
19. Rapamycin-based graft-versus-host disease prophylaxis increases the immunosuppressivity of myeloid-derived suppressor cells without affecting T cells and anti-tumor cytotoxicity.
Scheurer J; Reisser T; Leithäuser F; Messmann JJ; Holzmann K; Debatin KM; Strauss G
Clin Exp Immunol; 2020 Dec; 202(3):407-422. PubMed ID: 32681646
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation.
Tawara I; Koyama M; Liu C; Toubai T; Thomas D; Evers R; Chockley P; Nieves E; Sun Y; Lowler KP; Malter C; Nishimoto N; Hill GR; Reddy P
Clin Cancer Res; 2011 Jan; 17(1):77-88. PubMed ID: 21047980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
